Coastline Trust’s Castle Biosciences CSTL Stock Holding History

Coastline Trust’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-100	Closed	-$2.85K	–	434
2024 Q3	$2.85K	Buy	+100	New	+$2.54K	﹤0.01%	412

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Coastline Trust's CSTL Position: Q4 2024 in Review

Coastline Trust sold out of Castle Biosciences (CSTL) in Q4 2024, closing a stake of 100 shares — an estimated $2.85K sold.

Coastline Trust first reported a position in CSTL in Q3 2024 and held it in 1 quarter. The position peaked at $2.85K in Q3 2024. 197 funds tracked by Wall St. Rank hold CSTL as of Q4 2024.

Coastline Trust reported no remaining Castle Biosciences position as of Q4 2024 after selling out during the quarter.
Coastline Trust sold 100 Castle Biosciences shares in Q4 2024, an estimated $2.85K.
Coastline Trust first reported a position in Castle Biosciences in Q3 2024 and held it in 1 quarter.
Coastline Trust's Castle Biosciences position peaked at $2.85K in Q3 2024.
197 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2024.

Based on Coastline Trust's 13F filing for Q4 2024, filed 13 Feb 2025.